Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 10/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.47 |
| ▸ | NAAA | Q02083 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL912535 | 0.95 | DUT (0.55) | DUTL3MBTL1CRBNNAAAPDE3A | |
| SCHEMBL2215255 | 0.93 | DUT (0.54) | DUTL3MBTL1NAAAPDE3A | |
| SCHEMBL2990980 | 0.89 | L3MBTL1 (0.53) | DUTL3MBTL1CRBNPKM | |
| SCHEMBL4348697 | 0.84 | L3MBTL1 (0.59) | DUTL3MBTL1CRBNPKM | |
| SCHEMBL30903387 | 0.82 | DUT (0.62) | DUTL3MBTL1CRBNNAAAPDE3A | |
| SCHEMBL6102943 | 0.82 | CRBN (0.56) | DUTL3MBTL1CRBNPKM | |
| SCHEMBL24263706 | 0.81 | DUT (0.55) | DUTL3MBTL1CRBNNAAAPKM | |
| SCHEMBL5017263 | 0.81 | L3MBTL1 (0.58) | DUTL3MBTL1CRBNNAAAPKM | |
| SCHEMBL5016828 | 0.81 | DUT (0.55) | DUTL3MBTL1CRBNNAAAPKM | |
| SCHEMBL6864606 | 0.81 | DUT (0.57) | DUTL3MBTL1CRBNPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120051575-A | Detection of modified nucleobases in nucleic acid samples | 豪夫迈·罗氏有限公司 | 2025-05-27 | — | — | CN | claimed |
| WO-2023154314-A1 | SPIRO PIPERIDINE DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-08-17 | — | — | WO | disclosed |
| US-7423048-B2 | Compounds for treating fundic disaccomodation | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-09-09 | — | — | US | disclosed |
| US-7081453-B2 | Compounds for treating impaired fundic relaxation | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-07-25 | — | — | US | disclosed |
| US-20060142318-A1 | Compounds for treating fundic disaccomodation | VAN EMELEN KRISTOF | 2006-06-29 | — | — | US | disclosed |
| EP-1296987-B1 | COMPOUNDS FOR TREATING IMPAIRED FUNDIC RELAXATION | JANSSEN PHARMACEUTICA NV (BE) | 2005-12-07 | — | — | EP | disclosed |
| US-20040019051-A1 | Compounds for treating impaired fundic relaxation | JANSSEN-CILAG S.A. (ES) | 2004-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019051-A1 | Compounds for treating impaired fundic relaxation | CNR2, CNR1, CBR1 | DUT 2173/4885L3MBTL1 2887/4885CRBN 1300/4885 |
| US-20060142318-A1 | Compounds for treating fundic disaccomodation | ALK, ADORA1, CHRM2 | DUT 2400/4885L3MBTL1 1929/4885CRBN 1734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.